The activity of Ec-SOD was markedly lower in BMPR2 mutation patients in our present study, possibly due to the decreased bioavailability of NO and/or decreased responsiveness to NO in PAH. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.